Purpose of review Surgery for high-risk prostate cancer (PCa) is applied frequently nowadays. Nevertheless, this approach is still surrounded by many controversies. The present review discusses the most recent literature regarding surgery for high-risk PCa.
INTRODUCTION
In developed countries, prostate cancer (PCa) is the most prevalent cancer with 648 400 new cases, taking third place in cancer mortality with an estimated 136 500 deaths in 2008 [1] . In the USA approximately 238 590 new cases of PCa with 29 720 cancer related deaths have been estimated for 2013 and PCa would account for 28% of incident cancers in men [2] . In the European Union, the number of newly diagnosed cases increased from 145 000 in 1996 to 345 000 in 2006 and PCa represents the third cause of cancer-related death in men [3] . Despite the dramatic increase in diagnosis, the number of deaths attributed to the disease over the same time period remained almost unchanged (75 000 in 1996 vs. 67 800 in 2006) [3, 4] .
A fair proportion of patients still present at diagnosis with high-risk PCa. Indeed, Cooperberg et al. [5] evaluated the trend in high-risk PCa in the United States between 1990 and 2007. They revealed an evolution in the number of patients with highrisk PCa, defined as PSA level >20 ng/mL, a Gleason score of !8 and/or cT3a, from 27.4% in 1990-1994 to 21.7% in 1995-1999 Furthermore, in the recently published European Randomized Study of Screening for PCa, 9.8% of the patients had T3/T4 tumors and 8.8% had Gleason score > 7 in the screening arm, whereas in the control arm, these figures were 19.5 and 15.8%, respectively [6] .
Several authors and international scientific organizations use different definitions of high-risk PCa, each defining slightly different patient populations: D'Amico [7] , National Comprehensive Cancer Network [8] , American Urological Association [9] European Association of Urology [10] , Radiation Therapy Oncology Group [11] , Cancer of the Prostate Risk Assessment Score [12] . Yossepowitch et al. [13] showed that patients with high-risk PCa did not have a uniformly poor prognosis when treated with radical prostatectomy and depending on the definition used, the 10-year cumulative PCa-specific mortality ranged between 3 and 11% [14] .
Differences in outcome could reasonably be influenced not only by the specific definition used, but also by clinical understaging [15, 16] and Gleason score downgrading at final histopathology [17] .
THE NATURAL EVOLUTION OF HIGH-RISK PROSTATE CANCER
Albertsen et al. [18] reported in 2005 the 20-year outcomes of patients with localized PCa managed by observation or androgen deprivation therapy (ADT) alone. They concluded that patients with highgrade PCa have a high probability of dying from PCa within 10 years of diagnosis [Gleason score 8-10, 121 deaths per 1000 person-years, confidence interval (CI) 95% 90-156]. At 20 years, the estimated risk of dying from PCa was 60-90% (depending on the age of the patient) when managed expectantly or hormonal therapy alone.
A Swedish population-based study assessed 15-year mortality for men with PCa treated with noncurative intent. The database contained data on 30 159 patients with high-risk PCa, defined as stage T3 or prostate specific antigen (PSA) level 20 to less than 50 ng/ml or Gleason score ! 8, and 10 315 patients with regionally metastatic PCa, defined as stage N1 or T4 or PSA level 50-100 ng/ml. The 10 and 15-year PCa mortality of the high-risk PCa group were 28.8 and 35.5%, whereas these numbers were 41.3 and 49.1%, respectively, for regionally metastatic disease [19] .
It is clear from these figures that patients with high-risk PCa, when not receiving aggressive local treatment, are truly at a very elevated risk of diseaserelated mortality.
THE RATIONALE OF SURGERY FOR HIGH-RISK PROSTATE CANCER
The management of high-risk PCa is one of the most compelling challenges in urology. In the absence of randomized trials comparing the true benefit of currently available treatment modalities (i.e., surgery, radiotherapy, ADT or a combination of these), it is very difficult to properly counsel patients on the optimal treatment. Cooperberg et al. [20] recently published the local variation and time trends in primary treatment of localized PCa. Data were analyzed from 36 clinical sites that contributed data to the Cancer of the Prostate Strategic Urologic Research Endeavor registry. According to the D'Amico risk groups among 11 892 patients, 1790 (15.1%) had high-risk PCa. Of those, 3.2% opted for active surveillance, 7.5% for brachytherapy, 18.1% for external radiotherapy, 32.8% for hormonal therapy, 6.1% underwent cryotherapy and 32.2% underwent radical prostatectomy.
Radical prostatectomy combined with an extended pelvic lymph node dissection (e-PLND) is a valid strategy accepted by international guidelines [8, 10] . The putative benefits of radical prostatectomy as first-line treatment are to achieve tumor volume reduction and optimal local control. Furthermore, pathologic examination of the resection specimen and postoperative PSA allows for better treatment individualization by carefully
KEY POINTS
The natural history of high-risk and very-high-risk PCa is characterized by a 15-year cancer-specific mortality of 35 and 49%, respectively.
High-risk PCa patients treated by radical prostatectomy have variable survival outcomes according to different high-risk definitions. Nevertheless, independent of the definition, highly convincing long-term cancer-specific survival rates have been described, far surpassing those seen with noncurative approaches.
Frequent downgrading and downstaging, and a possible therapeutic role of local tumor debulking support radical prostatectomy and e-PLND as primary management strategy in a multimodality treatment.
Innovative nomograms can aid to predict specimenconfined disease and positive lymph node rates after radical prostatectomy and e-PLND.
Minimally invasive surgery is showing promising results, but further studies are needed to support its role compared to open radical prostatectomy and e-PLND as the gold standard.
selecting patients that require adjuvant treatment. Indeed, in high-risk PCa, radical prostatectomy must often be combined with adjuvant radiotherapy or ADT [21] [22] [23] [24] [25] .
Two randomized controlled trials have been conducted, comparing radical prostatectomy with watchful waiting. After a follow-up of 15 years, the Scandinavian Prostate Cancer Group (SPCG)-4 trial showed that radical prostatectomy was associated with a reduction of all-cause mortality, relative risk (RR) ¼ 0.75 (0.61 to 0.92) and death from PCa, RR ¼ 0.62 (0.44 to 0.87) [26] . In a post-hoc analysis, Vickers et al. created competing risk models estimating the benefit of radical prostatectomy for an individual patient. These models suggested that surgery seems unequivocally of benefit for patients who have Gleason score ¼ 8, or Gleason score ¼ 7, T2 PCa [27] . The overall survival (OS) and cancerspecific survival (CSS) benefit seen in SPCG-4 could not be reproduced for the overall study population in another prospective randomized trial. After a median follow-up of 10 years, the PIVOT trial showed that radical prostatectomy did not significantly reduce all-cause mortality: hazard ratio (HR) ¼ 0.88 (0.71-1.08); P ¼ 0.22, nor did radical prostatectomy significantly reduce PCa mortality: HR ¼ 0.63 (0.36 to 1.09); P ¼ 0.09. According to a preplanned subgroup analysis, PCa mortality was lower in the radical prostatectomy group than in the observation group among men with PSA > 10 ng/ml (5.6 vs. 12%, P ¼ 0.02) and men with high-risk PCa (9.1 vs. 17.5%) [28] .
RECENTLY PUBLISHED RESULTS OF SURGERY FOR HIGH-RISK PROSTATE CANCER
According to biopsy Gleason score, patients are categorized as high-risk when it is 8 or higher. The biopsy Gleason score is a significant predictor of pathologic outcomes as well as one of the key predictors of clinical outcomes after radical prostatectomy [29, 30] . One of the reasons to opt for surgery in high-grade PCa is the high rate of downgrading between the biopsy Gleason score and the Gleason score of the resected specimen. Indeed, several studies demonstrated that one third of patients with a biopsy Gleason score 8 are downgraded to Gleason score 7 [31] [32] [33] . These men in particular may benefit most from potentially curative resection.
Several studies described good outcomes after radical prostatectomy in the context of a multimodal approach for patients with a biopsy Gleason score of at least 8. Biochemical progression-free survival (BPFS) at 5-year and 10-year follow-up ranged from 35-51 and 24-39%, respectively, whereas CSS at 5-year, 10-year and 15-year followup was 96, 84-88 and 66%, respectively [14, 17, 32, 34, 35] .
The definition of high-risk PCa considers also patients with PSA > 20 ng/ml and initial PSA has long been recognized as an important risk indicator. Recent reports in patients with a PSA > 20 ng/ml who underwent surgery as initial therapy within a multimodal approach, demonstrated a BPFS at 5, 10 and 15-year follow-up ranging between 40-63, 25-48 and 25%, respectively. CSS at 5, 10 and 15-year ranges between 93-97, 83-91 and 71-78%, respectively [14, [34] [35] [36] [37] [38] .
Radical prostatectomy can provide an acceptable treatment option for well selected patients with stage cT3a, [39, 40] ]. Although more than half of the patients received adjuvant hormonal therapy and/or radiotherapy in most of the presented studies, the high CSS suggests that local cancer control remains especially important in men with locally advanced disease.
It also appears that in well selected patients, radical prostatectomy combined with adjuvant or salvage treatment when needed may result in better outcomes than radiotherapy alone, whereas published outcomes are similar to the combination of radiotherapy and adjuvant ADT. However, these findings should ideally be confirmed in randomized, prospective studies [45] .
RADICAL PROSTATECTOMY FOR VERY-HIGH-RISK PROSTATE CANCER
Patients at very high risk have stage cT3b-T4 PCa at diagnosis and according to international guidelines, radical prostatectomy is considered optional in highly selected very-high-risk PCa patients, strictly in the context of a multimodality treatment approach [8, 10] . Very-high-risk PCa patients present two specific challenges: there is a need for local control as well as a need to treat any microscopic metastases, likely to be present, but undetectable until disease progression. The optimal treatment approach will therefore often necessitate multiple modalities. The exact combinations, timing and intensity of treatment continue to be strongly debated [10] .
Gontero et al. [46] compared the results of radical prostatectomy in very-high-risk PCa with those having localized PCa. There were no significant differences in surgical morbidity except for blood transfusion, operative time and lymphoceles. The OS and CSS at 7 years were 76.7 and 90.2% in the advanced disease group and 88.4 and 99.3% in the organ-confined disease group, respectively. Recently, Joniau et al. [47] described single-center results of radical prostatectomy in 51 patients presenting with cT3b or cT4 PCa. Intriguingly, overstaging in this group was still substantial, with roughly one-third of patients having organ-confined disease (7.8%) or capsular perforation only (29.4%). Overstaged patients were often cured by surgery alone, as 35.3% of the whole group did not receive any form of neoadjuvant/adjuvant treatment and 21.6% remained free of additional therapies at a median follow-up of 108 months.
In cT3b-T4 PCa, 5 and 10-year CSS was 88-92 and 92%, respectively. Five and 10-year OS was 73-88 and 71%, respectively [47, 48] . These results suggest that radical prostatectomy may be a reasonable step in the context of a multimodality treatment approach in selected patients with cT3b-T4 PCa, provided that the tumor is not fixed to the pelvic wall or invaded in the urethral sphincter. Nevertheless, data describing outcomes after surgery in very-high-risk PCa are extremely scarce and further studies are urgently needed in this domain.
Another feature to attribute a very-high-risk stratification is the presence of positive regional lymph nodes (any cT, N1). Although the incidence of lymph node metastasis has dramatically decreased in the PSA era, lymph node invasion is still diagnosed in up to 40% of patients submitted to e-PLND [49] . Historically, patients with lymph node invasion were considered to be affected by systemic and noncurable disease, and thus were not considered suitable for a surgical approach. Recently, Engel et al. [50] found a doubled risk of overall mortality (HR 2.042; CI 95% 1.59-2.63; P < 0.0001) when radical prostatectomy was abandoned compared with completed radical prostatectomy for patients in whom positive lymph nodes were found at the time of surgery. These results were later confirmed in single-center series from a large tertiary referral center [51] . It was hypothesized that the observed survival benefit imposed by radical prostatectomy in these advanced stages could be explained by cytoreduction of an androgen-resistant cell reservoir, characterized by the prostate itself [52] . The evidence of an improved effectiveness of ADT in patients who undergo local treatment would indeed support that hypothesis [53] .
In a landmark trial on the role of adjuvant ADT following surgery in node positive PCa, it was demonstrated that early adjuvant ADT was associated with improved survival outcomes compared with deferred treatment [54] . Recently, a retrospective multicenter matched-case analysis has shown that patients with positive lymph nodes at the time of radical prostatectomy could benefit from not only early ADT, but also associated maximal local control through radiotherapy. Indeed, the combination of radiotherapy and ADT was associated with a 5 and 10-year CSS of 95 and 86%, respectively, compared with 88 and 70% for ADT alone (P ¼ 0.004) [55] .
IS THERE A ROLE FOR MINIMALLY INVASIVE SURGERY IN THE TREATMENT OF HIGH-RISK PROSTATE CANCER?
Traditionally, radical prostatectomy in high-risk PCa has been performed by the open approach. However, during the last years, an increasing number of publications have appeared on the use of minimally invasive techniques, particularly robot-assisted radical prostatectomy (RARP) [56] [57] [58] [59] . RARP series had positive margin rates between 20 and 48.8% and short-term biochemical recurrence rates between 13 and 47.2%. This variability could be justified by differences in the definitions used to describe highrisk PCa, small sample sizes and differences in the surgical teams' experience. Indeed, for open radical prostatectomy, it has already been shown that surgical experience could impact on positive margin rates. In about 15 years, positive margin rates passed from 75 to 10.4% in a tertiary referral center [60] .
Recently, a comparative study among three risk groups, according to D'Amico classification, showed that high-risk patients treated with RARP and e-PLND had 53% positive margins compared to low risk (12.5%) and intermediate risk (27.1%) . Also, the high-risk group had a significantly higher percentage of positive nodes and biochemical recurrence. The same authors could not find any statistically significant difference in trifecta outcomes (oncological outcome, continence and potency) between risk groups (P ¼ 0.552) [61] .
A recent retrospective analysis [62] studied 913 patients with high-risk PCa (Gleason score ! 8, PSA ! 20 ng/ml, clinical stage !cT2c) treated with open radical prostatectomy or minimally invasive radical prostatectomy (MIRP) with e-PLND and aimed at comparing pathological and short-term biochemical recurrence-free survival outcomes for different therapeutic approaches. 81.4% underwent open radical prostatectomy, 11.5% were operated by RARP and 7.1% by laparoscopic radical prostatectomy (LRP). The authors demonstrated a biochemical recurrence-free survival of 56.3, 67.8 and 41.1%, respectively (P ¼ 0.6) and a positive surgical margin (PSM) rate of 29.4, 34.3 and 27.7% for open retropubic radical prostatectomy (ORRP), RARP and LRP, respectively. An e-PLND was performed and 10.8% of positive nodes was found in ORRP groups compared with 3.5% in MIRP. The authors concluded that equivalent rates of PSM and short-term BPFS between open radical prostatectomy and MIRP were observed. However, major limitations were differences in the cumulative number of high-risk factors, short follow-up, nonstandardized e-PLND and nerve sparing indications.
Four hundred and ten patients with NCCN highrisk PCa were analyzed to compare open radical prostatectomy to RARP. The authors concluded that the two techniques were comparable in terms of early (2-4 years) recurrence-free survival and oncological results, without a statistically significant difference between groups. Longer follow-up is needed to demonstrate equal oncological control. This is especially important because in the RARP group, fewer patients had PLND compared with the open radical prostatectomy group (63 vs. 96%, P < 0.01) and there was a lower rate of lymph node involvement (4 vs. 15%, P < 0.01) linked to a significant difference in lymph node yield (11 vs. 15, P < 0.01). At multivariate analysis, the authors found a higher risk of PSM for RARP [odds ratio (OR) 5.05; 95% CI 1.02-25.0, P ¼ 0.05] in the first 4 years of their experience, although this difference seems to decrease afterwards [63] .
A strong debate surrounds the feasibility and role of robotic surgery in performing e-PLND. A recent series of 143 robotic e-PLND in intermediate/high-risk PCa according to the D'Amico classification showed a median number of 20 (range 9-65) excised nodes with positive node rates of 13% without Clavien-Dindo complications in 82% of cases [64] confirming the technical feasibility of the procedure with minimally invasive surgery.
These promising results from minimally invasive surgery have to be confirmed by randomized clinical trials. Such will be vital in order to achieve optimal oncological, functional and sexual outcomes, bearing in mind the high risk of cancer progression in this group of patients.
NOVEL PATIENT SELECTION TOOLS FOR SURGERY IN HIGH-RISK PROSTATE CANCER
Achieving tumor volume reduction and optimal local control represent the main benefits of radical prostatectomy as first-line treatment in high-risk PCa. It has been estimated that 35-76% of high-risk PCa patients at 10 years after radical prostatectomy are alive without the need for any form of secondary therapy for the treatment of disease progression [14] .
The importance of PSM has already been confirmed in recent studies, which have associated PSM characteristics, such as number and length of PSM and Gleason score at the margin site, to a higher risk of biochemical recurrence [65] [66] [67] . From this point of view, the possibility to predict presence of specimen-confined disease (SCD) (pT2-3a, R0, N0) could help clinicians to select patients who might benefit from radical prostatectomy monotherapy. Indeed, a recent publication described a 37% SCD rate following radical prostatectomy for high-risk PCa (Gleason score ! 8, PSA ! 20 ng/ml, !cT3), whereas 63% evidenced non-SCD (pT3b/4, PSM, N1). SCD was associated with a 5 and 10-year cancer-specific mortality-free rates of 99.7 and 98.2%, respectively, compared with 94.5 and 87.6% in patients with non-SCD [68 && ]. Age, PSA, clinical tumor stage and biopsy Gleason score were identified as independent predictors of SCD at multivariate analysis (P < 0.04) and were combined into a novel nomogram that provides predictions of SCD with discriminative accuracy of 72%.
The impact of age and comorbidity at the moment of radical prostatectomy for high-risk PCa (PSA ! 20 ng/ml, biopsy Gleason score ! 8 and cT!3) was recently studied using a competing risk approach in a large multicenter database containing 3828 patients. Depending on age and comorbidity at the time of radical prostatectomy, the 10-year CSM ranged between 5.1 and 12.8% confirming the favorable results of radical prostatectomy in high-risk PCa. The present series demonstrates that OCM is the main cause of death in the total study population, with the exception of healthy (Charlson index ¼ 0) and young ( 59 years) patients in whom CSM is the main cause of death. These data demonstrate that radical prostatectomy may be more important in young and healthy patients, as well as in older (!70 years) patients with a low comorbidity score, as these patients are at risk of dying from their disease. Conversely, because of higher OCM rates and very low CSM rates, elderly patients with multiple comorbidities seem to be less amenable for radical prostatectomy [69 && ]. An ePLND [70, 71] , defined as excision of external iliac, internal iliac, obturator and common iliac lymph nodes is recommended by the European Association of Urology guidelines for patients with high-risk PCa [10] . The prevalence of positive lymph nodes has been estimated to be up to 40% for patients who undergo PLND, but it is difficult to predict LND infiltration before the intervention; an innovative instrument to predict the probability of positive lymph nodes at e-PLND has been recently proposed [72 && ]. Clinical stage, primary biopsy Gleason grade and percentage of positive cores were all independent predictors of lymph node positivity (all P 0.006) at multivariable analysis and together with PSA at diagnosis, they represent the elements of an updated nomogram to predict the presence of positive nodes with a good predictive accuracy (area under the curve 87.6%). It has been calculated that a cut-off of 5% would spare e-PLND in 65% of patients with 1.5% of false negatives.
Recently, a modified e-PLND scheme [73
&&
] has been proposed, including the presacral area. The authors demonstrated in a prospective study that a standard e-PLND (external iliac, obturator and internal iliac areas) is associated with 24% missed positive lymph nodes, whereas their proposed modified dissection template only missed 13% of positive nodes. From this series, it is clear that patients considered at increased risk of positive nodes according to validated nomograms, should receive a modified e-PLND in order to treat maximally those patients at risk.
CONCLUSION
Radical prostatectomy with e-PLND can achieve prolonged disease control and good cancer-specific survival in patients with high-risk PCa. In over onethird of patients, the disease is confined to the resection specimen at pathology and those patients have excellent cancer-specific survival rates at long follow-up. Nevertheless, it is clear that in many patients, surgery alone will not control the disease and multimodality therapy is needed to optimize cancer control.
Growing experience with minimally invasive surgery may further open up opportunities for improved functional outcomes with less surgical trauma. Nevertheless, longer follow-up and formal comparisons are needed.
In recent publications, a more accurate definition of high-risk PCa and the creation of novel clinicopathological tools have been presented, supporting surgeons in patient selection to avoid overtreatment of less aggressive cancers and undertreatment of truly lethal cancer types.
